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Abstract
Nicotine dependence as a result of smoking is a chronically relapsing disorder with detrimental effects. However, fortunately for
smokers, an armamentarium of smoking cessation aids is available in the forms of nicotine replacement therapy (NRT), non-nicotinic drugs (namely varenicline and bupropion), and the novel nicotine vaccines, each with their own mode of action to moderate
nicotine addiction. This paper analyzes the mechanism of action associated with nicotine addiction and the various methods of
combat, or at the very least, attenuation of the addiction.
Introduction
role, if any, in causing smoking-induced diseases, the addicThough incognito, nicotine addiction has been proven to
tion to nicotine, which leads to sustained smoking use, is
be the true killer in the seemingly innocent activity of
the proximate cause of these diseases (Onor et al., 2017).
smoking, for it reinforces the desire to smoke. To preNicotine (C10H14N2) is a plant alkaloid found in the
vent the myriad adverse effects of smoking, smokers
tobacco plant (Onor et al., 2017) that consists of a pyrineed to work very hard to break nicotine addiction
dine and pyrrolidine ring, each one possessing a tertiary
through smoking cessation. Nonetheless, many smokers
amine (Escobar-Chávez et al., 2011). The pKa of the pyrfind themselves dealing with many ups and downs in the
idine nitrogen is 3.04 and the pKa of the pyrrolidine niquitting process. It comes as no surprise that nicotine
trogen is 7.84 under standard conditions. Based on these
addiction is therefore identified as a “chronic condition”
characteristics, nicotine’s distribution exists among three
by The US Clinical Practice Guideline, as many smokers
forms, depending on the pH of the solution. An increase
need to make several attempts before they
successfully wean themselves off completely
(Fagerström & Hughes, 2008). Smoking is the
second most expensive chronic health condition in the United States, with an estimated
economic cost of 300 billion dollars per year
(Jordan & Xi, 2018).Yet, stopping smoking can
reverse the biological and economical damage caused by smoking (Benowitz, 2010).
Understandably, 70% of smokers admit that Figure 1.The various forms of nicotine based on pH (Centers for Disease Control and
they would like to quit. Every year, about 40% Prevention, 2010).
quit for at least a day. However, due to the extreme difin acidity of solution increases the fraction of protonated
ficulty to abstain, about 45 million Americans currently
molecules; conversely, a more basic environment increassmoke tobacco. Moreover, the 80% who attempt to quit
es the fraction of the unprotonated, or free base, form
on their own return to smoking within a month. Each
(Figure 1).Although all forms of nicotine are highly soluble
year, only 3% of smokers quit successfully and remain abin water and can easily dissolve in lung fluids and blood,
stinent one year later, highlighting the critical need for
the unprotonated nicotine smoke particles are volatile,
effective long-term smoking treatments (Benowitz, 2010).
whereas the protonated form is not. Conventionally, a
sample of particulate matter from cigarette smoke is not
Methods
acidic enough to cause the protonated form to dominate.
This comprehensive review is based on critical analyThus, a higher percentage of unprotonated nicotine can
ses of literature obtained using various databases availrapidly cross biological lipid membranes and be deposited
able through The Touro College Library online, such
in the respiratory tract (Centers for Disease Control and
as PubMed and ProQuest. The National Center for
Prevention, 2010). Nicotine begins to reach the brain ten
Biotechnology (NCBI) website was also useful in
seconds after inhalation and its concentration continues
provi di ng additional source material.
to increase gradually (Dani et al, 2011).
Blood concentrations of nicotine rise rapidly and peak
Nicotine Addiction
at the completion of smoking. The rapid absorption of
Ci garett e smoki ng i s a major cause of death, cardionicotine is attributed to the broad surface area of the
vascular disease, and pulmonary disease. It also presalveoli and small airways. This rapid rise allows the smokents the risk for various infections, osteoporosis, reproer to titrate and manipulate the level of nicotine during
ductive disorders, adverse postoperative events, delayed
smoking, which makes smoking the most reinforcing and
wound healing, duodenal and gastric ulcers, and diabetes
dependence-producing form of nicotine administration
(Benowitz, 2010). Although nicotine itself plays a minor
(Benowitz et al., 2009).
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Essentially, pharmacologic feedback, learned factors, genetics, and environmental factors (including tobacco product design and marketing, stress, smoking cues, or peers
who smoke) contribute to nicotine addiction. Other factors include sex, age, mental illness, and substance abuse.
Although each of these features contributes, the one that
will be discussed with percipience is the pharmacological
interplay with nicotine addiction (Benowitz et al., 2009).
The pharmacological basis for nicotine use is enhancement of mood and augmentation of mental and physical
functions. Inhalation of smoke from a cigarette allows
nicotine from the smoke particles to diffuse through the
lungs, where it is rapidly absorbed into the pulmonary
venous circulation. From there, it moves quickly to the
left ventricle of the heart and to the systemic arterial circulation and brain. Based on human autopsy samples from
smokers, the liver, kidney, spleen, and lung have the highest
affinity for nicotine (Benowitz et al., 2009). Subsequently,
the nicotine enters arterial circulation to be moved from
the lungs to the brain with high affinity, where it binds to
nicotinic acetylcholine receptors (nAchRs), ligand-gated
ion channels that normally bind a neurotransmitter acetylcholine (Benowitz, 2010).
NAchRs are pentameric structures consisting of a combination of five different subunits, including nine α subunits (α2 through α10) and three β subunits (β2 through
β4), resulting in at least 12 unique nAchR subtypes that
have been identified thus far. The α4β2 receptor, though,
is the prime mediator of nicotine dependence. As seen
in positron emission tomography studies in humans,
smoking a full nicotine cigarette nearly saturated α4β2
receptor occupancy. In fact, when disruption of the β2
subunit gene was tested in mice, the behavioral effects of
nicotine were eliminated. Similarly, the α4 subunit is an
important determinant of sensitivity to nicotine. This was
confirmed when a mutation affecting a single nucleotide
in the pore-forming region of the receptor gene in mice
made it hypersensitive to the effects of nicotine. These
observations strongly implicate α4β2 nAchRs in nicotine
addiction and illustrate the α4β2 receptor as a potentially
attractive medicinal target for treatment of the addiction
(Jordan & Xi, 2018).
The smoker craves nicotine to propagate dopamine
overflow in the pleasure-seeking areas of the brain. The
α4β2 are located on the dopamine (DA) cells of the mesolimbic system. The system is comprised of projections
from DA neurons in the ventral tegmental area (VTA)
to the nucleus accumbens (NAc), the part of the brain
responsible for reward, pleasure, laughter, aggression, and
fear, and the prefrontal cortex. Nicotine binding to α4β2
receptors on VTA DA cells increases neuronal excitability
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and neurotransmitter release, opening the ligand-gated
ion channel, and allowing Ca2+ and Na+ to cascade intracellularly, which stimulates DA release to NAc (Figure 2).
This is the underlying effect of nicotine’s reward cascade,
as dopamine serves as a pleasure signal and mood modulator and is critical for reinforcing nicotinic effects (Jordan
& Xi, 2018).
When studied under laboratory conditions, nicotine
elicits classic addictive responses (Dani et al, 2011). In
order to reap the rewarding feeling associated with nicotine and avoid withdrawal symptoms, smokers must maintain a certain nicotine level. Repetitive exposure to nicotine leads to neuroadaptation and tolerance to nicotine’s

Figure 2. Schematic diagram of the mesolimbic DA projection
pathway in the human brain. Nicotine activates a4b2 nAChRs
located on DA neurons located in the VTA, as illustrated (Xi, 2010).

effects, and accumulation of nicotine in the body leads to
a more substantial withdrawal reaction if cessation is attempted. Common withdrawal symptoms include anxiety,
difficulty concentrating, and irritability, all of which can
last for days, weeks, or longer (Onor et al., 2017).
As neuroadaptation occurs, the number of binding
sites on the nicotinic cholinergic receptors in the brain
increases.This causes desensitization, wherein a ligand-induced closure and unresponsiveness of the receptor
occurs due to the profusion of ligand infiltration. Thus,
the feelings of craving and withdrawal are exacerbated
during periods of abstinence due to the mitigated levels of dopamine and other neurotransmitters. However,
during a smoking period, binding to the α4β2 cholinergic
receptors alleviates the need for nicotine. To circumvent
withdrawal symptoms, smokers will sustain sufficient levels of plasma nicotine (Benowitz, 2010).
It comes as no surprise that nicotine withdrawal is
extremely taxing on the smoker. Such repercussions are
powerful incentives to take up smoking again (Benowitz,
2010). Fortunately for smokers, there is an expansive market of nicotine treatments that promote smoking cessation, some of them in the form of nicotine replacement
therapy (NRT), non-nicotinic drugs such as bupropion and
varenicline, and finally, the emergence of nicotine vaccines.

Effective Treatments for Nicotine Addiction

Nicotine Replacement Therapy (NRT)
Nicotine’s rapid rate of absorption and entry to the brain
are key factors responsible for the high abuse potential.
Unlike cigarettes, nicotine replacement therapy (NRT)
products such as gums, inhalers, and transdermal patches can help relieve the physical withdrawal symptoms
by providing gradual increments of nicotine without the
damaging chemicals found in cigarette smoke (Jordan &
Xi, 2018). The gradual distribution of nicotine results in
low abuse liability of NRTs. Although NRT doesn’t completely eliminate withdrawal symptoms since it does not
provide rapid and high levels of nicotine, NRT may provide a coping mechanism, making cigarettes less enticing
to smoke (Molyneux, 2004) and increasing the rate of
quitting by 50 to 70% (Stead et al., 2012). NRTs are well
tolerated and have minimal adverse effects, but are most
effective when used in conjunction with intense behavioral support (Molyneux, 2004).
In 1984, transmucosally delivered nicotine polacrilex, or
nicotine gum, was introduced as the first effective NRT to
serve as a smoking cessation aid, as approved by the US
Food and Drug Administration (FDA). It is not chewed like
ordinary confectionary gum, as it must be intermittently
chewed and held in the mouth for over 30 minutes to
achieve optimal release of nicotine. The absolute dose of
nicotine absorbed systemically is much less than the nicotine content of the gum, in part because considerable nicotine is swallowed with first-pass metabolism (Benowitz et
al., 2009), where it gets metabolized in a specific location
other than the location of interest, reducing the concentration that enters systemic circulation (Herman &Santos,
2019). The dosage is slowly decreased until it is no longer
required (Wadgave & Nagesh, 2016).
To satisfy the behavioral hand-to-mouth ritual of smoking, the nicotine oral inhaler was introduced to the NRT
market. Contrary to its label, the inhaler is mainly delivered
to the oral cavity, esophagus, and stomach, and negligibly to
the lungs. Because absorption is mainly through the oral
mucosa, a slow absorption rate of nicotine is achieved, akin
to that of nicotine gum (Wadgave & Nagesh, 2016).
In a parallel fashion, nicotine patches deliver nicotine
at a relatively steady rate when applied to and readily
absorbed through the skin. In fact, the patch is the form
that delivers nicotine at the slowest rate when compared
to the other forms of NRT. A chief advantage of nicotine patches is the simplicity of user compliance, since
the patch can be placed on the skin in the morning and
worn for the duration of the day.The patches are available
in a range of doses, allowing users to gradually decrease
their nicotine intake over the span of several weeks or
longer to ensure a proper adjustment to lower nicotine

levels until they can attain a nicotine-free state. The rate
of nicotine release is controlled by the permeability of
the skin, rate of diffusion through a polymer matrix, and
rate of passage through membranes in the various patches on the market. In all cases, there is an initial lag time of
1 hour before nicotine enters the bloodstream, followed
by continued systemic absorption once the patch is removed, the latter due to the vestiges of nicotine in the
skin (Benowitz et al., 2009). Current evidence supports
the safety of long-term use of nicotine patches for nicotine treatment (Wadgave & Nagesh, 2016).
Non-Nicotinic Drugs
Bupropion (Wellbutrin)
The first non-nicotine drug to treat nicotine addiction
was introduced in 1997. Bupropion (amfebutamone),
marketed as Wellbutrin and Zyban among others (Fava,
et al., 2005), an amphetamine-based drug, is a reuptake
inhibitor of dopamine into neuronal synaptic vesicles
and a blocker of nicotine’s activation of several neuronal nAChRs. Bupropion undergoes metabolic transformation to an active metabolite, 4-hydroxybuproprion,
through hepatic cytochrome CYP2B6, (Foley et al., 2006).
Bupropion’s structure is akin to nicotine, rendering it a
compatible competitor (Figure 3). Originally developed
as an antidepressant, a systematic review of 44 clinical
trials found that sole therapy with bupropion significantly
increased long-term (≥6 months) smoking abstinence, affirming its efficacy as an anti-smoking agent (Onor et al.,
2017). It should be noted that the antismoking effect does
not seem to correlate with its antidepressant effect, as
bupropion is equally as effective for smoking cessation for
individuals with and without depression (Roddy, 2004).

Figure 3.The chemical structures of bupropion (left) and nicotine
(right) (National Center for Biotechnology Information).
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When nicotine infiltrates the blood and crosses the
blood brain barrier, there is a release of dopamine into
the synaptic cleft of neurons in the dopaminergic pathways. After nicotine levels subside, dopamine reuptake
into the axon terminal vesicles occurs. Bupropion is
thought to inhibit this dopamine reuptake. In vivo studies
have also shown that bupropion antagonizes the effects
of nicotine at the postsynaptic acetylcholine nicotinic receptor (Wilkes, 2008). During withdrawal, bupropion may
attenuate symptoms by mimicking the effects of nicotine
on dopamine (Warner & Shoaib, 2005). These effects may
explain how bupropion inhibits the reinforcing effects
of nicotine, though it is still unclear whether bupropion
offers any long-term relapse prevention following termination of treatment. Nonetheless, both pragmatic and observational trials of bupropion have shown that approximately 1 in 5 smokers will successfully remain abstinent
for at least a year post-treatment (Wilkes, 2008).
Varenicline (CHANTIX)
Cytisine is a naturally occurring insecticide found in the
leaves and seeds of Cytisus laburnum (golden rain tree).
During World War II, soldiers smoked leaves of this tree
in lieu of tobacco. Both varenicline and cytisine target
the α4β2 receptor, where varenicline was developed to
improve binding to the receptor to enhance efficacy of
smoking cessation. However, the cytisine structure did
not lead to a viable drug candidate. In due course, a series
of efforts based on analgesic bicyclic benzazepines, one of
which was unveiled as a potent α4β2 nAchR antagonist,
served as a novel template that led to the development
of varenicline, branded as CHANTIX. FDA approval was
based on randomized clinical trials conducted in 3659
subjects in the United States. The subjects, all of whom
were chronic smokers, averaged 43 years of age and reported smoking an average of 21 cigarettes per day for
the previous 25 years. The primary outcome measured
abstinence from smoking, which came in at a 44% rate,
a significant improvement over bupropion (30%) and
placebo (18%). Secondary outcomes, such as the urge to
smoke and withdrawal symptoms, were likewise improved
in varenicline-treated subjects over placebo (Jordan & Xi,
2018). In 2006, varenicline received FDA approval, and it
was highly touted as an aid to quit smoking (Fagerström
& Hughes, 2008).
Like bupropion, varenicline has a somewhat parallel configuration to its nicotine competitor in order to
operate as an appropriate replacement. In fact, in vitro
binding assays indicate that varenicline’s affinity for the
α4β2 receptor (Ki = .15 nM) is higher than that of nicotine (Ki = 1.6 nM) and cytisine (Ki = 0.23 nM) (Jordan
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& Xi, 2018). Varenicline has the following chemical name:
7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3- h]
[3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
(Figure 4). Varenicline has a molecular weight of 361.35
Daltons and is highly soluble in water (Pfizer Labs, 2016).
With varenicline, dopamine is still released, but less so
than with nicotine. Since the α4β2 had been identified to
have the highest sensitivity to nicotine, it had become a
potential target for the smoking cessation drug.Varenicline
was developed to have a high affinity for the α4β2 neuronal nicotinic acetylcholine receptors in the mesolimbic
dopamine system and stimulate receptor-mediated activity,
but at a significantly lower level than nicotine. Varenicline’s
highly selective nature ensures that it will bind more po-

Figure 4.The chemical structures of nicotine (left), cytisine (middle),
and varenicline (right) (Xi, 2010).

tently to α4β2 receptors than to other common nicotinic
or non-nicotinic receptors (Pfizer Labs, 2016).
As a result of being a partial agonist, varenicline displays
both agonist and antagonist effects. Partial agonists have
been reviewed thoroughly as a method of attenuating
nicotine addiction. Partial agonists bind to nAchRs but
do not elicit the maximum response of a full agonist, and
instead depend on receptor occupancy by other ligands.
For instance, in the presence of a full agonist like nicotine,
a partial agonist would behave as an antagonist by occupying the receptor site, thereby minimizing nicotine’s effects
at the receptor. However, in the absence of nicotine, a
partial agonist would behave as an agonist by mitigating
nicotine withdrawal symptoms through triggering a degree of dopamine release (Jordan & Xi, 2018).
Given that continuous abstinence rates across studies
remain low (18-30% with varenicline; 4-10% with placebo), novel and more effective treatments may be required.
However, since FDA approval in 2006, incoming reports
have been continuing to demonstrate varenicline’s efficacy for smoking cessation over the alternatives. For
example, in a randomized trial involving 376 participants
over the span of 52 weeks, varenicline resulted in higher
abstinence rates from smoking (55.9%) when compared
to transdermal NRT (43.2%), highlighting varenicline’s
progress (Jordan & Xi, 2018).

Effective Treatments for Nicotine Addiction

Nicotine Vaccines
With the advent of the novel nicotine vaccines, smokers
have an alternative course of action through which they
can quit smoking. Currently undergoing clinical trials, the
goal of the vaccine is to generate antibodies that sequester
nicotine in the blood and hinder the pharmacological effects by preventing access into the brain. Thus, the vaccine
brims with potential for treatment of nicotine addiction
and relapse prevention (Goniewicz & Delijewski, 2013).
Based on the assumption that a rapid increase in brain
nicotine levels induces feelings of reward, preventing nicotine from entering the brain is an intriguing idea with
precedent in other, similar treatments. Using antibodies
to bind a drug and thus disabling it from crossing the
blood-brain barrier was first tested in the realm of heroin
addiction and extended to nicotine and cocaine addiction
(Raupach et al., 2012).
Since nicotine is too small to elicit a response from the
immune system, nicotine is not immunogenic. In order
to elicit an immune response, nicotine or a structurally
similar hapten needs to be paired with a larger carrier
protein, thus producing a conjugate vaccine (Goniewicz
& Delijewski, 2013). Vaccination administers an immunogenic substrate that activates T and B cells, leading to
the formation of specific antibodies within the individual,
imprinting the response in immunological memory. By
virtue of this mechanism, this approach has been shown
to yield longer lasting protection (Raupach et al., 2012).
When nicotine enters the body, the vaccine causes
it to bind to the nicotine-specific antibodies, forming a
complex too large to cross the blood-brain barrier. Thus,
there is no nicotine-induced cerebral stimulation for
the smoker and the impression received by the smoker
is comparable to smoking a cigarette without nicotine
(Escobar-Chávez et al., 2011).
The success of this immunological strategy hinges on immunogenicity of the vaccine, affinity of antibodies, and specificity of antibodies (Raupach et al., 2012). Immunogenicity
refers to the antibody serum concentration. A vaccine
must elicit and maintain a high antibody serum concentration throughout the period of interest in order to be
maximally effective (Escobar-Chávez et al., 2011).
The primary measure of antibody affinity to the target
drug can be measured by the binding equilibrium constant, Ka. The Ka is defined by Ka = [NicAb]/[Nic][Ab].
[NicAb] represents the plasma volume concentration of
bound nicotine-antibody complexes, and [Nic] and [Ab]
denote the volume concentrations of unbound drug and
unbound antibody, respectively. Hence, in order to calculate the percentage of bound nicotine, data regarding
the amount of antibody present in circulation must be

obtained beforehand. The Ka should be high enough to
bind to nicotine and low enough to allow for unbound
nicotine release and elimination (Goniewicz & Delijewski,
2013). However, extremely high affinity may be disadvantageous, as saturation of all antibodies compromises efficacy for subsequent nicotine doses (Fahim et al., 2011).
Interestingly, the interaction of antibodies with nicotine is reversible and each antibody binds to and releases nicotine many times, much like a juggler catches and
releases multiple sticks many times. Thus, it is observed
that the binding capacity of the antibodies for nicotine is
far in excess than the expected stoichiometric calculation
(Escobar-Chávez et al., 2011).
Specificity refers to the extent to which the elicited
antibodies bind to nicotine in preference to other molecules (Raupach et al., 2012). Greater specificity reduces
competition from other molecules, thus improving safety and minimizing the likelihood of adverse side effects
(Escobar-Chávez et al., 2011). This has practical applications for the design of conjugate vaccines. For example,
one recent study showed that using longer rather than
shorter linkers, amino acid sequences used to separate
multiple domains in a protein (Reddy Chichili et al., 2013),
increases antibody selectivity to nicotine. Additionally,
linker position influences specificity. Linkers that are distant from the prime sites of metabolism (i.e. attached to
the 6- rather than 5- position of the pyridine ring) help
enhance antibody selectivity (Raupach et al., 2012).
In order to maintain an ideal serum antibody concentration, repeated administration of the nicotine-conjugate
system in the form of the vaccine is required. The first
vaccination administered causes a primary immune response, comparable to when the organism had its initial
encounter with an infectious antigen. Each subsequent
administration acts as a “planned infection,” which uses
memory about the antigens during the production of antibodies. Therefore, a faster and more effective response
to the subsequent vaccinations is anticipated (Goniewicz
& Delijewski, 2013).
Due to the prolonged effect that nicotine vaccines provide, they have an advantage over the existing pharmacotherapies (Shen et al., 2012, as cited
in Goniewicz & Delijewski, 2013) and are a critical
addition to the pharmacological smoking cessation
aids. The relapse rate is minimal since only bimonthly booster shots are required to achieve a high level
of antibodies. Thus, patient adherence to the necessary protocol can significantly improve. Nevertheless,
early clinical trials have casted some doubts in that
many patients may not elicit a sufficient antibody response. To circumvent this issue, novel carriers and/
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or adjuvants with immunogenic properties can be
introduced to stimulate a more potent immune response (Cerny et al., 2009, as cited in Goniewicz &
Delijewski, 2013).
For those who attain high levels of antibodies, vaccination has been shown to be effective in achieving and
maintaining abstinence (Goniewicz & Delijewski, 2013).
Vaccines against nicotine are at an advanced stage of
clinical trials but have not yet been approved for treatment of individuals (Escobar-Chávez et al., 2011). Future
strategies for enhanced specificity that the vaccine can
provide in conjunction with a high affinity to nicotine
and increased antibody level offer an effective avenue for
smoking-cessation (Goniewicz & Delijewski, 2013).
Discussion and Conclusion:
After reviewing the various smoking cessation techniques,
it seems that a combination of a few would be the most
viable option. The smoker can implement preliminary arrangements with the use of NRT. NRT may be useful for
those who want to attenuate the smoking habit but do
not want to put a halt to it completely, known as quitting
“cold turkey.” The choice of NRT can be guided by the
patient’s preference, though it may be wise to have a firstline agent in conjunction with NRT; however, healthcare
professionals must learn the benefits and potential detriments of different types of NRT before guiding patients in
its potential use (Wadgave & Nagesh, 2016).
Smokers who find that they are unsuccessful with NRT
can choose an alternative method. Although nicotine vaccines have an advantage over existing pharmacotherapies
in that they have a prolonged effect and require substantially less cooperation from patients with bimonthly
booster shots, data from clinical trials suggest that many
patients may not produce sufficient antibody response
(Goniewicz & Delijewski, 2013), suggesting that it may
not be the most pragmatic approach.
Since nicotine addiction is primarily responsible in
impeding smoking cessation and long-term abstinence,
it seems that the most prudent option would be a modality that targets the activity at the α4β2 receptor, the
prime mediator of nicotine dependence. Where bupropion therapy aims to alleviate the withdrawal symptoms
experienced during the transition state to a steady state
of neurotransmitter activity, as does NRT, varenicline was
developed to selectively target nicotine activity at the
receptor that leads to the addiction, a seemingly more
robust approach. Though varenicline presents a surfeit
of undesirable side effects, some in the forms of nausea, abnormal dreams, taste perversion, and headaches
(Burke et al., 2016), these effects may prove manageable
98

and worthwhile under a cost-benefit analysis. The strong
rationale for targeting the α4β2 receptor with a partial agonist, coupled with promising findings from clinical studies, reinforce varenicline’s efficacy and safety as
a reliable smoking cessation aid. Upregulation of these
receptors and adaptation lead to the compulsive use of
nicotine to maintain homeostasis, both of which render
the α4β2 receptor an effective candidate for pharmacologic intervention. However, patients and providers
should determine whether to use varenicline only after
an assessment of the potential risks and benefits. The
efficacy of varenicline can be improved in combination
with NRT and bupropion, especially for smokers who are
more heavily dependent on nicotine (Burke et al., 2016).
Greater understanding of the exact mechanisms of these
drugs, particularly bupropion, could lead to the development of drugs that are more effective in promoting
smoking abstinence (Warner & Shoaib, 2005).
All things considered, nota bene that relapse is often
prominent in a patient’s attempt to quit smoking. The average patient will quit four or five times before reaching
complete cessation, an important point to convey to patients to prevent disillusionment and hopelessness during
recovery (Woody et al., 2008).
Essentially, the adverse health effects associated with
cigarette smoking are numerous and continual efforts to
reduce the prevalence of smoking are imperative (Onor
et al., 2017). Nevertheless, due to futile attempts to quit,
many smokers feel demoralized and incapable of taking
action towards quitting. However, there are options
available to the smoker. Whether in the form of NRT,
non-nicotinic drugs (namely varenicline and bupropion),
or the novel nicotine vaccines, nicotine addiction can be
mitigated to aid the journey towards recovery.
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